The Journal of PHARMACOLOGY And Experimental Therapeutics

Correction to "Pharmacological Characterization of Olodaterol, a Novel Inhaled β_2-Adrenoceptor Agonist, Exerting a 24-Hour-Long Duration of Action in Preclinical Models"

In the above article [Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, and Schnapp A (2010) *J Pharmacol Exp Ther* **334:**53–62], the authors have recently identified a mistake in the calculation of parts of the functional selectivity data in the originally published article. The selectivity data for olodaterol in the Abstract and in Table 3, and the selectivity ratios for formoterol, salmeterol, and isoprenaline in table 3 are incorrect in the original article.

In the Abstract and in Table 3, the correct olodaterol β_2 selectivity ratios for the hβ_1- and the hβ_3-AR should be 241 and 2299, respectively. The corrected Table 3 is given below. Please note that the primary functional data underlying the calculations have not changed. Although the resulting newly calculated selectivity values are numerically different, the pharmacological assessment of olodaterol remains the same.

The online versions have been corrected.

The authors regret this error and apologize for any confusion and inconvenience it may have caused.

TABLE 3
Functional properties of different β_2-AR agonists against the three human β-adrenoceptor subtypes.

	hß$_1$		hß$_2$		hß$_3$		Ratio β_1/β_2	Ratio β_3/β_2
	pEC_{50}	IA	pEC_{50}	IA	pEC_{50}	IA		
		%		%		%		
Isoprenaline	9.27 ± 0.08	100	8.58 ± 0.08	100	7.86 ± 0.07	100	0.2	5
Olodaterol	7.55 ± 0.08	52 ± 8*	9.93 ± 0.07	88 ± 2	6.57 ± 0.08	81 ± 2*	241	2299
Formoterol	7.83 ± 0.06	91 ± 4	9.73 ± 0.10	97 ± 3	7.60 ± 0.07	100 ± 2	80	135
Salmeterol	6.08 ± 0.07	40 ± 6*	9.90 ± 0.04	54 ± 7*	6.15 ± 0.17	56 ± 3*	6603	5619